Healthcare

UAE investment drives Middle East biopharma transformation

UAE investment in genomics, AI and advanced manufacturing is reshaping biopharmaceutical research. The initiatives include large-scale genome programs, AI-discovered preclinical candidates and a precision-medicine partnership in Abu Dhabi.

A report on the UAE’s biopharmaceutical sector describes national investment in genomics, artificial intelligence and advanced manufacturing. These technologies are being developed as part of a wider effort to strengthen medicine discovery, development and production inside the country.

The Emirati Genome Program aims to collect one million genetic samples nationwide. The UAE Reference Genome study is analyzing more than 50,000 samples and building infrastructure intended to support disease prevention, precision treatment and healthcare research.

The report also highlights AI-driven drug discovery in Abu Dhabi. In 2025, Insilico Medicine’s Abu Dhabi center nominated the UAE’s first fully AI-discovered preclinical candidates for oncology and non-opioid pain, completing discovery workflows in under 12 months.

A June 2026 partnership between Abu Dhabi’s Department of Health and Boehringer Ingelheim is cited as another step toward using the emirate’s genomics capabilities for precision-medicine research. Together, these initiatives connect population-scale genetic data with AI-assisted pharmaceutical development and clinical research.

Original source: Big News Network

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI